دورية أكاديمية
أعرض في EDS

A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding

التفاصيل البيبلوغرافية
العنوان: A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding
المؤلفون: Corral M, Ferko N, Hogan A, Hollmann SS, Gangoli G, Jamous N, Batiller J, Kocharian R
المصدر: ClinicoEconomics and Outcomes Research, Vol Volume 8, Pp 507-519 (2016)
بيانات النشر: Dove Medical Press, 2016.
سنة النشر: 2016
المجموعة: LCC:Medicine (General)
LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: cost, soft tissue bleeding, hepatic bleeding, surgical bleeding, coagulopathic, fibrin sealant patch, hospital, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
الوصف: Mitra Corral,1 Nicole Ferko,2 Andrew Hogan,2 Sarah S Hollmann,2 Gaurav Gangoli,1 Nadine Jamous,3 Jonathan Batiller,1 Richard Kocharian1 1Ethicon BioSurgery, Somerville, NJ, USA; 2Cornerstone Research Group, Burlington, ON, Canada; 3Ethicon Biosurgery, Wokingham, Berkshire, UK Background: Despite hemostat use, uncontrolled surgical bleeding is prevalent. Drawbacks of current hemostats include limitations with efficacy on first attempt and suboptimal ease-of-use. Evarrest® is a novel fibrin sealant patch that has demonstrated high hemostatic efficacy compared with standard of care across bleeding severities. The objective of this study was to conduct a hospital cost analysis of the fibrin sealant patch versus standard of care in soft tissue and hepatic surgical bleeding. Methods: The analysis quantified the 30-day costs of each comparator from a hospital perspective. Published US unit costs were applied to resource use (ie, initial treatment, retreatment, operating time, hospitalization, transfusion, and ventilator) reported in four trials. A “surgical” analysis included resources clinically related to the hemostatic benefit of the fibrin sealant patch, whereas a “hospital” analysis included all resources reported in the trials. An exploratory subgroup analysis focused solely on coagulopathic patients defined by abnormal blood test results. Results: The surgical analysis predicted cost savings of $54 per patient with the fibrin sealant patch compared with standard of care (net cost impact: −$54 per patient; sensitivity range: −$1,320 to $1,213). The hospital analysis predicted further cost savings with the fibrin sealant patch (net cost impact of −$2,846 per patient; sensitivity range: −$1,483 to −$5,575). Subgroup analyses suggest that the fibrin sealant patch may provide dramatic cost savings in the coagulopathic subgroup of $3,233 (surgical) and $9,287 (hospital) per patient. Results were most sensitive to operating time and product units. Conclusion: In soft tissue and hepatic problematic surgical bleeding, the fibrin sealant patch may result in important hospital cost savings. Keywords: cost, soft tissue bleeding, hepatic bleeding, surgical bleeding, coagulopathic, fibrin sealant patch, hospital, health economics
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1178-6981
Relation: https://www.dovepress.com/a-hospital-cost-analysis-of-a-fibrin-sealant-patch-in-soft-tissue-and--peer-reviewed-article-CEOR; https://doaj.org/toc/1178-6981
URL الوصول: https://doaj.org/article/79035bee5070413e83525038aa3af1d6
رقم الأكسشن: edsdoj.79035bee5070413e83525038aa3af1d6
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:11786981